Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00

Key Points

• Citigroup raised its price target on Royalty Pharma from $50.00 to $66.00 and maintained a "buy" rating, implying roughly a 31.5% upside, while the consensus among analysts remains a "Buy" with an average target of $53.71.
• Royalty Pharma's Q1 results showed an EPS beat (reported $1.46 vs. $1.33 expected) but revenue missed expectations ($621.99M vs. ~$840M); the company generated strong operating cash flow (~$718M) and raised full‑year 2026 portfolio receipts guidance to $3.325B–$3.45B.
• Insider selling has been notable (CFO sold 34,791 shares; insiders sold 139,164 shares worth ~$6.62M over three months) even as shares trade around $50.20 (market cap ≈ $29B) and institutional ownership remains high (~54%).

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price boosted by analysts at Citigroup from $50.00 to $66.00 in a report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price target suggests a potential upside of 31.47% from the company's previous close.

Other analysts have also issued reports about the company. Wall Street Zen lowered Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 14th. The Goldman Sachs Group restated a "buy" rating on shares of Royalty Pharma in a research report on Thursday, February 12th. TD Cowen reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, February 27th. Morgan Stanley increased their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an "overweight" rating in a report on Friday, April 10th. Finally, Weiss Ratings raised shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $53.71.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded down $0.52 during trading on Thursday, hitting $50.20. 5,602,082 shares of the company's stock traded hands, compared to its average volume of 3,523,412. The company has a market cap of $28.96 billion, a PE ratio of 37.19, a PEG ratio of 3.22 and a beta of 0.40. The firm's fifty day moving average price is $47.52 and its 200 day moving average price is $42.66. Royalty Pharma has a twelve month low of $32.15 and a twelve month high of $51.65. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The firm had revenue of $621.99 million for the quarter, compared to analysts' expectations of $839.97 million. Analysts forecast that Royalty Pharma will post 5.08 earnings per share for the current year.

Insider Activity

In related news, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 139,164 shares of company stock valued at $6,624,902. 18.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Royalty Pharma

Large investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company's stock valued at $6,342,000 after purchasing an additional 160,191 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company's stock worth $2,490,000 after purchasing an additional 13,489 shares during the period. Focus Partners Wealth acquired a new position in Royalty Pharma during the first quarter worth approximately $264,000. Intech Investment Management LLC increased its position in Royalty Pharma by 41.0% during the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company's stock worth $1,494,000 after buying an additional 13,951 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Royalty Pharma by 21.4% in the second quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company's stock valued at $56,184,000 after buying an additional 274,960 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma News Roundup

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: JPMorgan raised its price target to $58 and upgraded RPRX to "overweight," implying roughly mid-teens upside from the current quote. Read More.
• Positive Sentiment: Company reported Q1 results showing portfolio receipts +10% and royalty receipts +13%, generated $718M of operating cash flow, and raised full‑year 2026 Portfolio Receipts guidance to $3,325M–$3,450M — a clear positive for near‑term revenue visibility. Read More.
• Positive Sentiment: Q1 EPS beat consensus ($1.30 reported vs. ~$1.22 expected) and management emphasized confident growth on the earnings call, which supports valuation expectations if receipts continue to ramp. Read More.
• Positive Sentiment: Analyst and media writeups flagged an upbeat tone from the Q1 earnings call (management signaling confident growth), reinforcing the bullish interpretation of the quarter. Read More.
• Positive Sentiment: Coverage noted RPRX hit a 52‑week high, reflecting strong recent investor interest and momentum into the quarter. Read More.
• Neutral Sentiment: Royalty Pharma announced participation in several investor conferences in May, which should increase visibility but is a modest near‑term catalyst. Read More.
• Neutral Sentiment: Full Q1 earnings transcripts and call materials are available for deeper review (useful for active investors evaluating guidance and pipeline exposure). Read More. Read More.
• Negative Sentiment: Reported revenues for the quarter came in well below some consensus figures cited by analysts (various sources show revenue materially under prior estimates), which could cap upside and explain short‑term selling pressure despite the EPS beat and guidance raise. Read More.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.